companydata.dkDraupnir Bio ApS: Financial statements 2022
CVR: 38546880
Draupnir Bio ApS (CVR 38546880) has filed annual accounts for 2022. In 2022, the company reported a net result of DKK -39,890,000 compared with DKK -67,044,000 the year before. Equity amounted to DKK 18,566,000. The solvency ratio was 65.4%. The company had 13 employees in the financial year.
- Profit/Loss
- -39,890,000 kr.
- Equity
- 18,566,000 kr.
- Total Assets
- 28,383,000 kr.
- Employees
- 13
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | - | -39.9 mio. | 18.6 mio. | 13 |
| 2021 | - | - | -67 mio. | 53.5 mio. | - |
| 2020 | - | - | -60.6 mio. | 54.2 mio. | - |
| 2019 | - | -15.9 mio. | -15.2 mio. | 52 mio. | 2 |
| 2018 | - | -1.8 mio. | -2.1 mio. | -1.8 mio. | 1 |
Keep an eye on Draupnir Bio ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Draupnir Bio ApS has published its annual report for 2021. The net result was DKK -67,044,000.
As of February 24, 2022, Ivan Burkov has joined the board of directors of Draupnir Bio ApS.
As of February 24, 2022, Roel Bulthuis has left the board of directors of Draupnir Bio ApS.
About Draupnir Bio ApS
Draupnir Bio ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Andrew Thomas Hotchkiss. The company's owners include Novo Holdings A/S, Coöperatieve Gilde Healthcare IV U.A. and Danmarks Eksport- og Investeringsfond. Equity amounted to DKK 15,256,000.